|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects transport |
ISO |
ABCC2 protein affects the transport of 2-amino-3-methylimidazo(4,5-f)quinoline |
CTD |
PMID:16611851 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of AHR protein |
CTD |
PMID:27644595 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
decreases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in decreased expression of AKR1B10 mRNA |
CTD |
PMID:26198647 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
increases mutagenesis |
ISO EXP |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased mutagenesis of APC gene |
CTD |
PMID:7846077 PMID:8608549 PMID:12034317 |
|
NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696
|
|
G |
Aprt |
adenine phosphoribosyl transferase |
multiple interactions |
ISO |
[NAT2 protein results in increased susceptibility to 2-amino-3-methylimidazo(4,5-f)quinoline] which results in increased mutagenesis of APRT gene [CYP1A2 protein co-treated with 2-amino-3-methylimidazo(4,5-f)quinoline] results in increased mutagenesis of APRT gene |
CTD |
PMID:2023932 PMID:9150757 |
|
NCBI chr19:50,626,201...50,628,491
Ensembl chr19:50,626,202...50,628,431
|
|
G |
Asf1a |
anti-silencing function 1A histone chaperone |
decreases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in decreased expression of ASF1A mRNA |
CTD |
PMID:26198647 |
|
NCBI chr20:32,893,962...32,908,808
Ensembl chr20:32,893,573...32,908,808
|
|
G |
Bik |
BCL2-interacting killer |
increases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of BIK mRNA |
CTD |
PMID:26198647 |
|
NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
|
|
G |
Casp3 |
caspase 3 |
increases cleavage increases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased cleavage of CASP3 protein 2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of CASP3 mRNA |
CTD |
PMID:35985368 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of CASP7 mRNA |
CTD |
PMID:35985368 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of CASP9 mRNA |
CTD |
PMID:35985368 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases activity |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in decreased activity of CAT protein |
CTD |
PMID:35985368 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in decreased expression of CDH1 protein |
CTD |
PMID:22094457 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression increases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in decreased expression of CDKN1A protein 2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of CDKN1A mRNA |
CTD |
PMID:22094457 PMID:31542801 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases mutagenesis multiple interactions |
EXP |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased mutagenesis of CTNNB1 gene [chlorophyllin affects the reaction [2-amino-3-methylimidazo(4,5-f)quinoline results in increased mutagenesis of CTNNB1 gene]] inhibits the reaction [GSK3B protein results in increased phosphorylation of and results in increased ubiquitination of CTNNB1 protein]; chlorophyllin affects the reaction [2-amino-3-methylimidazo(4,5-f)quinoline results in increased mutagenesis of CTNNB1 gene] |
CTD |
PMID:9515794 PMID:12628520 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
affects activity increases expression |
ISO |
CYP1A1 affects the activity of 2-amino-3-methylimidazo(4,5-f)quinoline 2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of CYP1A1 mRNA |
CTD |
PMID:2334931 PMID:27644595 PMID:31542801 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects metabolic processing increases expression multiple interactions increases activity affects response to substance |
ISO EXP |
CYP1A2 protein affects the metabolism of 2-amino-3-methylimidazo(4,5-f)quinoline 2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of CYP1A2 mRNA Quercetin inhibits the reaction [CYP1A2 results in increased activity of 2-amino-3-methylimidazo(4,5-f)quinoline] [CYP1A2 protein co-treated with 2-amino-3-methylimidazo(4,5-f)quinoline] results in increased mutagenesis of APRT gene CYP1A2 protein affects the susceptibility to 2-amino-3-methylimidazo(4,5-f)quinoline CYP1A2 protein results in increased activity of 2-amino-3-methylimidazo(4,5-f)quinoline; CYP1A2 results in increased activity of 2-amino-3-methylimidazo(4,5-f)quinoline [CYP1A2 protein co-treated with POR protein co-treated with OAT protein] results in increased susceptibility to 2-amino-3-methylimidazo(4,5-f)quinoline; CYP1A2 protein results in increased hydroxylation of and results in increased activity of 2-amino-3-methylimidazo(4,5-f)quinoline; CYP1A2 protein results in increased metabolism of and results in increased susceptibility to 2-amino-3-methylimidazo(4,5-f)quinoline |
CTD |
PMID:2023932 PMID:2334931 PMID:2655891 PMID:9581821 PMID:10503888 PMID:11752233 PMID:14725854 PMID:15728263 PMID:27644595 PMID:28160022 PMID:31542801 More...
|
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Fbxo30 |
F-box protein 30 |
decreases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in decreased expression of FBXO30 mRNA |
CTD |
PMID:26198647 |
|
NCBI chr 1:5,655,341...5,671,558
Ensembl chr 1:5,655,339...5,672,441
|
|
G |
Gpat3 |
glycerol-3-phosphate acyltransferase 3 |
increases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of GPAT3 mRNA |
CTD |
PMID:26198647 |
|
NCBI chr14:8,715,367...8,768,051
Ensembl chr14:8,714,373...8,766,490
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
[chlorophyllin affects the reaction [2-amino-3-methylimidazo(4,5-f)quinoline results in increased mutagenesis of CTNNB1 gene]] inhibits the reaction [GSK3B protein results in increased phosphorylation of and results in increased ubiquitination of CTNNB1 protein] |
CTD |
PMID:12628520 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
H2ax |
H2A.X variant histone |
increases expression increases phosphorylation |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of H2AX protein modified form 2-amino-3-methylimidazo(4,5-f)quinoline results in increased phosphorylation of H2AX protein |
CTD |
PMID:28160022 PMID:34510228 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
increases mutagenesis |
EXP |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased mutagenesis of HPRT1 gene |
CTD |
PMID:12467141 |
|
NCBI chr X:132,736,175...132,768,149
Ensembl chr X:132,736,096...132,768,154
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
increases mutagenesis |
EXP |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased mutagenesis of HRAS gene |
CTD |
PMID:2009133 PMID:8844820 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of JUN protein |
CTD |
PMID:22094457 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
increases mutagenesis |
EXP |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased mutagenesis of KRAS gene |
CTD |
PMID:8844820 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
increases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of LIF mRNA |
CTD |
PMID:26198647 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Nat2 |
N-acetyltransferase 2 |
increases response to substance multiple interactions |
ISO |
NAT2 protein results in increased susceptibility to 2-amino-3-methylimidazo(4,5-f)quinoline [CYP3A7 co-treated with NAT2] results in increased susceptibility to 2-amino-3-methylimidazo(4,5-f)quinoline; [NAT2 protein results in increased susceptibility to 2-amino-3-methylimidazo(4,5-f)quinoline] which results in increased mutagenesis of APRT gene; NAT2 protein results in increased metabolism of and results in increased susceptibility to 2-amino-3-methylimidazo(4,5-f)quinoline |
CTD |
PMID:7625840 PMID:9150757 PMID:28160022 |
|
NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
ISO |
[CYP1A2 protein co-treated with POR protein co-treated with OAT protein] results in increased susceptibility to 2-amino-3-methylimidazo(4,5-f)quinoline |
CTD |
PMID:9581821 PMID:10503888 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased cleavage of PARP1 protein |
CTD |
PMID:35985368 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO |
[CYP1A2 protein co-treated with POR protein co-treated with OAT protein] results in increased susceptibility to 2-amino-3-methylimidazo(4,5-f)quinoline |
CTD |
PMID:9581821 PMID:10503888 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases metabolic processing |
ISO |
PTGS1 protein results in increased metabolism of 2-amino-3-methylimidazo(4,5-f)quinoline |
CTD |
PMID:11159734 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases metabolic processing |
ISO |
PTGS2 protein results in increased metabolism of 2-amino-3-methylimidazo(4,5-f)quinoline |
CTD |
PMID:11159734 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rrm2b |
ribonucleotide reductase regulatory TP53 inducible subunit M2B |
increases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of RRM2B mRNA |
CTD |
PMID:21704725 |
|
NCBI chr 7:69,077,024...69,108,742
Ensembl chr 7:69,078,291...69,108,633
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of SLC7A11 mRNA |
CTD |
PMID:26198647 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Sult1b1 |
sulfotransferase family 1B member 1 |
increases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of SULT1B1 mRNA |
CTD |
PMID:31542801 |
|
NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
increases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of TGFBR1 protein |
CTD |
PMID:22094457 |
|
NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
increases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of TGFBR2 protein |
CTD |
PMID:22094457 |
|
NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of UGT1A1 mRNA |
CTD |
PMID:31542801 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Wnt1 |
Wnt family member 1 |
increases expression |
ISO |
2-amino-3-methylimidazo(4,5-f)quinoline results in increased expression of WNT1 protein |
CTD |
PMID:22094457 |
|
NCBI chr 7:129,938,604...129,942,651
Ensembl chr 7:129,938,604...129,942,651
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression multiple interactions decreases phosphorylation increases phosphorylation |
ISO EXP |
dactolisib results in decreased expression of AKT1 protein modified form dactolisib inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; mirdametinib promotes the reaction [dactolisib results in decreased phosphorylation of AKT1 protein] dactolisib inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; LEPR affects the reaction [dactolisib results in decreased phosphorylation of AKT1 protein] dactolisib increases phosphorylation of Akt in rat tumor grafts |
CTD RGD |
PMID:19435893 PMID:21464613 PMID:22415236 PMID:22949526 PMID:23151917 PMID:24758408 PMID:25640480 PMID:26983879 More...
|
RGD:152177690 |
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Chloroquine promotes the reaction [dactolisib affects the folding of and results in increased activity of BAX protein]; dactolisib affects the folding of and results in increased activity of BAX protein; dactolisib promotes the reaction [Chloroquine affects the folding of and results in increased activity of BAX protein] |
CTD |
PMID:23151917 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
affects expression |
ISO |
dactolisib affects the expression of BCL2L1 protein |
CTD |
PMID:25640480 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
affects expression |
ISO |
dactolisib affects the expression of BCL2L11 protein |
CTD |
PMID:25640480 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
dactolisib results in decreased expression of BIRC5 protein |
CTD |
PMID:22729845 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
increases activity increases cleavage multiple interactions |
ISO |
dactolisib results in increased activity of CASP3 protein dactolisib results in increased cleavage of CASP3 protein Chloroquine promotes the reaction [dactolisib results in increased cleavage of CASP3 protein]; dactolisib promotes the reaction [Chloroquine results in increased cleavage of CASP3 protein] |
CTD |
PMID:21372221 PMID:23151917 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage |
ISO |
Chloroquine promotes the reaction [dactolisib results in increased cleavage of CASP9 protein]; dactolisib promotes the reaction [Chloroquine results in increased cleavage of CASP9 protein] |
CTD |
PMID:23151917 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
decreases phosphorylation |
ISO |
dactolisib results in decreased phosphorylation of CCND1 protein |
CTD |
PMID:23651616 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
dactolisib results in increased expression of CDKN1A protein |
CTD |
PMID:23651616 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Ctsb |
cathepsin B |
affects localization multiple interactions |
ISO |
dactolisib affects the localization of CTSB protein [Chloroquine co-treated with dactolisib] affects the localization of CTSB protein |
CTD |
PMID:23151917 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
dactolisib inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:24758408 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
decreases phosphorylation increases response to substance multiple interactions |
ISO |
dactolisib results in decreased phosphorylation of EIF4EBP1 protein EIF4EBP1 protein modified form results in increased susceptibility to dactolisib Ku 0063794 inhibits the reaction [dactolisib results in decreased phosphorylation of EIF4EBP1 protein]; mirdametinib promotes the reaction [dactolisib results in decreased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:21372221 PMID:22415236 PMID:23151917 PMID:25640480 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
decreases activity |
ISO |
dactolisib results in decreased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
dactolisib inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; dactolisib inhibits the reaction [INS1 protein results in increased phosphorylation of OXSR1 protein]; dactolisib inhibits the reaction [INS1 protein results in increased phosphorylation of SLC12A3 protein]; dactolisib inhibits the reaction [INS1 protein results in increased phosphorylation of STK39 protein] |
CTD |
PMID:22949526 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
ISO |
LEPR affects the reaction [dactolisib results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:22949526 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Map1lc3a |
microtubule-associated protein 1 light chain 3 alpha |
increases metabolic processing affects localization |
ISO |
dactolisib results in increased metabolism of MAP1LC3A protein dactolisib affects the localization of MAP1LC3A protein |
CTD |
PMID:23651616 |
|
NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
dactolisib promotes the reaction [mirdametinib results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:22415236 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
dactolisib promotes the reaction [mirdametinib results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:22415236 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
affects expression multiple interactions |
ISO |
dactolisib affects the expression of MCL1 protein [dactolisib co-treated with (+)-JQ1 compound] affects the expression of MCL1 protein |
CTD |
PMID:25640480 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase |
increases response to substance |
ISO |
OGT mutant form results in increased susceptibility to dactolisib |
CTD |
PMID:23029544 |
|
NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146
|
|
G |
Oxsr1 |
oxidative stress responsive kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
dactolisib inhibits the reaction [INS1 protein results in increased phosphorylation of OXSR1 protein] dactolisib results in decreased phosphorylation of OXSR1 protein |
CTD |
PMID:22949526 |
|
NCBI chr 8:118,972,754...119,062,102
Ensembl chr 8:118,972,754...119,062,027
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
dactolisib results in increased cleavage of PARP1 protein |
CTD |
PMID:21464613 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
increases response to substance decreases response to substance |
ISO |
PIK3CA results in increased susceptibility to dactolisib PIK3CA results in decreased susceptibility to dactolisib |
CTD |
PMID:21372221 PMID:21633166 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Pten |
phosphatase and tensin homolog |
increases response to substance |
ISO |
PTEN gene mutant form results in increased susceptibility to dactolisib |
CTD |
PMID:21372221 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases expression |
ISO |
dactolisib results in decreased expression of RB1 protein modified form |
CTD |
PMID:23651616 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions decreases phosphorylation |
ISO |
mirdametinib promotes the reaction [dactolisib results in decreased phosphorylation of RPS6 protein] |
CTD |
PMID:21372221 PMID:21464613 PMID:21498705 PMID:22415236 PMID:23151917 PMID:25640480 More...
|
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation |
ISO |
dactolisib results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:21464613 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Slc12a3 |
solute carrier family 12 member 3 |
multiple interactions decreases phosphorylation |
ISO |
dactolisib inhibits the reaction [INS1 protein results in increased phosphorylation of SLC12A3 protein] dactolisib results in decreased phosphorylation of SLC12A3 protein |
CTD |
PMID:22949526 |
|
NCBI chr19:10,630,651...10,679,250
Ensembl chr19:10,631,393...10,669,091
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions decreases expression |
ISO |
bafilomycin A1 inhibits the reaction [dactolisib results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [dactolisib results in decreased expression of SQSTM1 protein] |
CTD |
PMID:23151917 PMID:23651616 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Stk39 |
serine threonine kinase 39 |
multiple interactions decreases phosphorylation |
ISO |
dactolisib inhibits the reaction [INS1 protein results in increased phosphorylation of STK39 protein] dactolisib results in decreased phosphorylation of STK39 protein |
CTD |
PMID:22949526 |
|
NCBI chr 3:52,913,583...53,179,060
Ensembl chr 3:52,913,585...53,179,060
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO |
epigallocatechin gallate inhibits the reaction [Imiquimod results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:24990399 PMID:29402411 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
decreases expression |
ISO |
imiquimod results in decreased expression of APEX1 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
imiquimod results in decreased expression of BCL2 protein |
CTD |
PMID:20033192 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Blm |
BLM RecQ like helicase |
decreases expression |
ISO |
imiquimod results in decreased expression of BLM mRNA |
CTD |
PMID:21878529 |
|
NCBI chr 1:134,409,832...134,496,073
Ensembl chr 1:134,409,857...134,484,312
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
decreases expression |
ISO |
imiquimod results in decreased expression of BRCA2 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
|
|
G |
Bst2 |
bone marrow stromal cell antigen 2 |
increases expression |
ISO |
Imiquimod results in increased expression of BST2 protein |
CTD |
PMID:31093508 |
|
NCBI chr16:18,216,605...18,220,979
Ensembl chr16:18,217,407...18,220,979
|
|
G |
Casp1 |
caspase 1 |
increases activity multiple interactions |
ISO |
Imiquimod results in increased activity of CASP1 protein [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Imiquimod] results in increased cleavage of CASP1 protein; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Imiquimod] results in increased cleavage of CASP1 protein] [Dronabinol inhibits the reaction [Imiquimod results in increased activity of CASP1 protein]] which affects the localization of IL1B protein; Dronabinol inhibits the reaction [Imiquimod results in increased activity of CASP1 protein] |
CTD |
PMID:31383729 PMID:36577999 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
increases activity increases cleavage |
ISO |
imiquimod results in increased activity of CASP3 protein imiquimod results in increased cleavage of CASP3 protein |
CTD |
PMID:12902443 PMID:20033192 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases secretion |
ISO |
Imiquimod results in increased secretion of CCL2 protein |
CTD |
PMID:34740670 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cd274 |
CD274 molecule |
increases expression |
ISO |
Imiquimod results in increased expression of CD274 protein |
CTD |
PMID:31093508 |
|
NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cd40 |
CD40 molecule |
increases expression multiple interactions |
ISO |
Imiquimod results in increased expression of CD40 protein LGMN gene mutant form inhibits the reaction [Imiquimod results in increased expression of CD40 protein] |
CTD |
PMID:22916010 PMID:31093508 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd80 |
Cd80 molecule |
increases expression |
ISO |
Imiquimod results in increased expression of CD80 protein |
CTD |
PMID:31093508 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions increases expression |
ISO |
[Imiquimod binds to and results in increased activity of TLR7 protein] which results in increased expression of CD86 protein; LGMN gene mutant form inhibits the reaction [Imiquimod results in increased expression of CD86 protein]; Tetrachlorodibenzodioxin promotes the reaction [[Imiquimod binds to and results in increased activity of TLR7 protein] which results in increased expression of CD86 protein] |
CTD |
PMID:21097750 PMID:22916010 PMID:31093508 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Chaf1a |
chromatin assembly factor 1 subunit A |
decreases expression |
ISO |
imiquimod results in decreased expression of CHAF1A mRNA |
CTD |
PMID:21878529 |
|
NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654
|
|
G |
Chaf1b |
chromatin assembly factor 1 subunit B |
decreases expression |
ISO |
imiquimod results in decreased expression of CHAF1B mRNA |
CTD |
PMID:21878529 |
|
NCBI chr11:33,200,894...33,221,076
Ensembl chr11:33,200,981...33,221,070
|
|
G |
Ctsb |
cathepsin B |
increases activity |
ISO |
Imiquimod results in increased activity of CTSB protein |
CTD |
PMID:22916010 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsk |
cathepsin K |
increases activity |
ISO |
Imiquimod results in increased activity of CTSK protein |
CTD |
PMID:22916010 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Ctsl |
cathepsin L |
increases activity |
ISO |
Imiquimod results in increased activity of CTSL protein |
CTD |
PMID:22916010 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Ctss |
cathepsin S |
increases activity |
ISO |
Imiquimod results in increased activity of CTSS protein |
CTD |
PMID:22916010 |
|
NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
[Pam(3)CSK(4) peptide co-treated with Antigens, Bacterial co-treated with Poly I-C co-treated with Lipopolysaccharides co-treated with FSL-1 lipoprotein, synthetic co-treated with imiquimod co-treated with Polyribonucleotides co-treated with ProMune] results in increased expression of CXCL10 protein; Particulate Matter inhibits the reaction [[Pam(3)CSK(4) peptide co-treated with Antigens, Bacterial co-treated with Poly I-C co-treated with Lipopolysaccharides co-treated with FSL-1 lipoprotein, synthetic co-treated with imiquimod co-treated with Polyribonucleotides co-treated with ProMune] results in increased expression of CXCL10 protein]; Vehicle Emissions inhibits the reaction [[Pam(3)CSK(4) peptide co-treated with Antigens, Bacterial co-treated with Poly I-C co-treated with Lipopolysaccharides co-treated with FSL-1 lipoprotein, synthetic co-treated with imiquimod co-treated with Polyribonucleotides co-treated with ProMune] results in increased expression of CXCL10 protein] |
CTD |
PMID:28655636 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases secretion multiple interactions increases expression |
ISO |
Imiquimod results in increased secretion of CXCL1 protein hispidulin inhibits the reaction [Imiquimod results in increased expression of CXCL1 mRNA] |
CTD |
PMID:22916010 PMID:32679548 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases metabolic processing multiple interactions affects metabolic processing increases chemical synthesis |
ISO |
CYP1A1 protein results in increased metabolism of Imiquimod CYP1A1 protein affects the reaction [beta-Naphthoflavone results in increased metabolism of Imiquimod] CYP1A1 protein affects the metabolism of Imiquimod [CYP1A1 protein results in increased metabolism of Imiquimod] which results in increased chemical synthesis of Imiquimod metabolite CYP1A1 protein results in increased chemical synthesis of Imiquimod metabolite |
CTD |
PMID:31111189 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions affects metabolic processing increases chemical synthesis increases metabolic processing |
ISO |
[CYP1A2 protein results in increased metabolism of Imiquimod] which results in increased chemical synthesis of Imiquimod metabolite CYP1A2 protein affects the metabolism of Imiquimod CYP1A2 protein results in increased chemical synthesis of Imiquimod metabolite CYP1A2 protein affects the reaction [beta-Naphthoflavone results in increased metabolism of Imiquimod] |
CTD |
PMID:31111189 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
increases metabolic processing |
ISO |
CYP2C19 protein results in increased metabolism of Imiquimod |
CTD |
PMID:31111189 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases metabolic processing |
ISO |
CYP2D6 protein results in increased metabolism of Imiquimod |
CTD |
PMID:31111189 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Ercc2 |
ERCC excision repair 2, TFIIH core complex helicase subunit |
decreases expression |
ISO |
imiquimod results in decreased expression of ERCC2 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102
|
|
G |
Ercc5 |
ERCC excision repair 5, endonuclease |
increases expression |
ISO |
imiquimod results in increased expression of ERCC5 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr 9:46,309,477...46,354,478
Ensembl chr 9:46,309,389...46,354,472
|
|
G |
Fancl |
FA complementation group L |
decreases expression |
ISO |
imiquimod results in decreased expression of FANCL mRNA |
CTD |
PMID:21878529 |
|
NCBI chr14:100,249,733...100,317,958
Ensembl chr14:100,248,875...100,314,255
|
|
G |
Fbh1 |
F-box DNA helicase 1 |
decreases expression |
ISO |
imiquimod results in decreased expression of FBH1 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr17:66,749,506...66,787,590
Ensembl chr17:66,749,534...66,787,590
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
decreases expression |
ISO |
imiquimod results in decreased expression of FGF2 |
CTD |
PMID:16368197 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Imiquimod] results in increased cleavage of GSDMD protein; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Imiquimod] results in increased cleavage of GSDMD protein] |
CTD |
PMID:36577999 |
|
NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055
|
|
G |
Gtf2h3 |
general transcription factor IIH subunit 3 |
decreases expression |
ISO |
imiquimod results in decreased expression of GTF2H3 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr12:32,009,010...32,025,484
Ensembl chr12:32,009,014...32,025,497
|
|
G |
Gtf2h4 |
general transcription factor 2H subunit 4 |
decreases expression |
ISO |
imiquimod results in decreased expression of GTF2H4 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr20:3,071,328...3,076,990
Ensembl chr20:3,071,328...3,076,984
|
|
G |
Gzmb |
granzyme B |
multiple interactions |
ISO |
Imiquimod results in increased expression of and results in increased secretion of GZMB protein |
CTD |
PMID:31093508 |
|
NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814
|
|
G |
H2ax |
H2A.X variant histone |
decreases expression |
ISO |
Imiquimod results in decreased expression of H2AX mRNA |
CTD |
PMID:21878529 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
[imiquimod binds to and results in increased activity of TLR7 protein] which results in increased expression of ICAM1 protein; Tetrachlorodibenzodioxin promotes the reaction [[imiquimod binds to and results in increased activity of TLR7 protein] which results in increased expression of ICAM1 protein] |
CTD |
PMID:21097750 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Imiquimod] results in increased secretion of IL10 protein |
CTD |
PMID:31082466 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il11 |
interleukin 11 |
multiple interactions decreases expression |
ISO |
ferulic acid inhibits the reaction [Imiquimod results in decreased expression of IL11 mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129
|
|
G |
Il11ra1 |
interleukin 11 receptor subunit alpha 1 |
multiple interactions decreases expression |
ISO |
ferulic acid inhibits the reaction [Imiquimod results in decreased expression of IL11RA1 mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr 5:56,931,824...56,941,408
Ensembl chr 5:56,935,516...56,941,408
|
|
G |
Il12a |
interleukin 12A |
multiple interactions increases secretion |
ISO |
[imiquimod binds to and results in increased activity of TLR7 protein] results in increased secretion of [IL12A protein binds to IL12B protein]; Tetrachlorodibenzodioxin inhibits the reaction [[imiquimod binds to and results in increased activity of TLR7 protein] results in increased secretion of [IL12A protein binds to IL12B protein]] Imiquimod results in increased secretion of IL12A protein |
CTD |
PMID:21097750 PMID:31093508 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions increases secretion increases expression |
ISO |
[Imiquimod binds to and results in increased activity of TLR7 protein] results in increased secretion of [IL12A protein binds to IL12B protein]; ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL12B mRNA]; LGMN gene mutant form inhibits the reaction [Imiquimod results in increased secretion of IL12B protein]; Tetrachlorodibenzodioxin inhibits the reaction [[Imiquimod binds to and results in increased activity of TLR7 protein] results in increased secretion of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:21097750 PMID:22916010 PMID:31054998 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13ra1 |
interleukin 13 receptor subunit alpha 1 |
multiple interactions increases expression |
ISO |
ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL13RA1 mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr X:115,348,822...115,408,682
Ensembl chr X:115,348,860...115,408,681 Ensembl chr11:115,348,860...115,408,681
|
|
G |
Il13ra2 |
interleukin 13 receptor subunit alpha 2 |
increases expression |
ISO |
Imiquimod results in increased expression of IL13RA2 mRNA |
CTD |
PMID:31054998 |
|
NCBI chr X:111,002,590...111,074,053
Ensembl chr X:111,002,592...111,072,381
|
|
G |
Il17a |
interleukin 17A |
multiple interactions increases expression increases secretion |
ISO |
(+)-JQ1 compound inhibits the reaction [Imiquimod results in increased expression of IL17A mRNA]; (+)-JQ1 compound inhibits the reaction [Imiquimod results in increased secretion of IL17A protein]; Chloroquine inhibits the reaction [Imiquimod results in increased expression of IL17A protein]; ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL17A mRNA]; ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL17A protein]; hispidulin inhibits the reaction [Imiquimod results in increased expression of IL17A mRNA]; Resveratrol inhibits the reaction [Imiquimod results in increased expression of IL17A mRNA]; SR 1078 inhibits the reaction [(+)-JQ1 compound inhibits the reaction [Imiquimod results in increased expression of IL17A mRNA]]; SR 1078 inhibits the reaction [(+)-JQ1 compound inhibits the reaction [Imiquimod results in increased secretion of IL17A protein]] Imiquimod results in increased expression of IL17A mRNA; Imiquimod results in increased expression of IL17A protein imiquimod results in increased secretion of IL17A protein |
CTD |
PMID:25965695 PMID:26149470 PMID:31054998 PMID:32679548 PMID:36002070 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il17b |
interleukin 17B |
decreases expression multiple interactions |
ISO |
Imiquimod results in decreased expression of IL17B mRNA ferulic acid inhibits the reaction [Imiquimod results in decreased expression of IL17B mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr18:55,141,194...55,145,565
Ensembl chr18:55,141,194...55,145,565
|
|
G |
Il17rb |
interleukin 17 receptor B |
decreases expression multiple interactions |
ISO |
Imiquimod results in decreased expression of IL17RB mRNA ferulic acid inhibits the reaction [Imiquimod results in decreased expression of IL17RB mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr16:5,180,431...5,194,125
Ensembl chr16:5,180,432...5,194,125
|
|
G |
Il18 |
interleukin 18 |
increases expression multiple interactions |
ISO |
Imiquimod results in increased expression of IL18 mRNA ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL18 mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il18bp |
interleukin 18 binding protein |
increases expression multiple interactions |
ISO |
Imiquimod results in increased expression of IL18BP mRNA hispidulin inhibits the reaction [Imiquimod results in increased expression of IL18BP mRNA] |
CTD |
PMID:32679548 |
|
NCBI chr 1:156,372,923...156,374,963
Ensembl chr 1:156,372,883...156,374,963
|
|
G |
Il18rap |
interleukin 18 receptor accessory protein |
multiple interactions increases expression |
ISO |
ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL18RAP mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr 9:42,768,112...42,800,964
Ensembl chr 9:42,768,220...42,800,959
|
|
G |
Il19 |
interleukin 19 |
increases expression multiple interactions |
ISO |
imiquimod results in increased expression of IL19 mRNA resveratrol inhibits the reaction [imiquimod results in increased expression of IL19 mRNA] |
CTD |
PMID:25965695 |
|
NCBI chr13:42,397,715...42,411,637
Ensembl chr13:42,399,138...42,405,473
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions increases expression |
ISO |
ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL1A mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases secretion multiple interactions increases expression |
ISO |
Imiquimod results in increased secretion of IL1B protein [Dronabinol inhibits the reaction [Imiquimod results in increased activity of CASP1 protein]] which affects the localization of IL1B protein; Cannabidiol inhibits the reaction [Imiquimod results in increased secretion of IL1B protein]; Dronabinol inhibits the reaction [Imiquimod results in increased expression of IL1B mRNA]; Dronabinol inhibits the reaction [Imiquimod results in increased secretion of IL1B protein]; JHW 015 inhibits the reaction [Imiquimod results in increased secretion of IL1B protein] Imiquimod results in increased expression of IL1B mRNA; Imiquimod results in increased expression of IL1B protein [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Imiquimod] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Imiquimod] results in increased secretion of IL1B protein; Chloroquine inhibits the reaction [Imiquimod results in increased expression of IL1B protein]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Imiquimod] results in increased secretion of IL1B protein]; ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL1B mRNA]; ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL1B protein]; hispidulin inhibits the reaction [Imiquimod results in increased expression of IL1B mRNA]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Imiquimod] results in increased secretion of IL1B protein] |
CTD |
PMID:18403674 PMID:31054998 PMID:31082466 PMID:31383729 PMID:32679548 PMID:34740670 PMID:36002070 PMID:36577999 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1f10 |
interleukin 1 family member 10 |
decreases expression multiple interactions |
ISO |
Imiquimod results in decreased expression of IL1F10 mRNA ferulic acid inhibits the reaction [Imiquimod results in decreased expression of IL1F10 mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr 3:7,072,511...7,075,439
Ensembl chr 3:7,072,511...7,075,439
|
|
G |
Il1rap |
interleukin 1 receptor accessory protein |
increases expression |
ISO |
Imiquimod results in increased expression of IL1RAP mRNA |
CTD |
PMID:31054998 |
|
NCBI chr11:74,062,999...74,199,530
Ensembl chr11:74,070,304...74,199,530
|
|
G |
Il2 |
interleukin 2 |
increases secretion |
ISO |
Imiquimod results in increased secretion of IL2 protein |
CTD |
PMID:34740670 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il20 |
interleukin 20 |
increases expression multiple interactions |
ISO |
Imiquimod results in increased expression of IL20 mRNA ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL20 mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr13:42,380,981...42,384,625
Ensembl chr13:42,380,981...42,384,625
|
|
G |
Il20rb |
interleukin 20 receptor subunit beta |
increases expression multiple interactions |
ISO |
Imiquimod results in increased expression of IL20RB mRNA ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL20RB mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr 8:100,979,085...101,010,829
Ensembl chr 8:100,980,383...101,009,942
|
|
G |
Il22ra1 |
interleukin 22 receptor subunit alpha 1 |
increases expression multiple interactions |
ISO |
Imiquimod results in increased expression of IL22RA1 mRNA ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL22RA1 mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr 5:147,961,496...147,986,296
Ensembl chr 5:147,961,349...147,986,296
|
|
G |
Il23a |
interleukin 23 subunit alpha |
increases secretion multiple interactions increases expression |
ISO |
imiquimod results in increased secretion of IL23A protein ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL23A mRNA]; ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL23A protein] Imiquimod results in increased expression of IL23A mRNA; Imiquimod results in increased expression of IL23A protein |
CTD |
PMID:25965695 PMID:26149470 PMID:31054998 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il27 |
interleukin 27 |
multiple interactions increases expression |
ISO |
ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL27 mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr 1:181,173,108...181,178,720
Ensembl chr 1:181,173,372...181,178,582
|
|
G |
Il33 |
interleukin 33 |
multiple interactions increases expression |
ISO |
ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL33 mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373
|
|
G |
Il36a |
interleukin 36, alpha |
increases expression multiple interactions |
ISO |
Imiquimod results in increased expression of IL36A mRNA ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL36A mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr 3:6,996,851...7,001,400
Ensembl chr 3:6,996,851...7,001,400
|
|
G |
Il36b |
interleukin 36, beta |
increases expression multiple interactions |
ISO |
Imiquimod results in increased expression of IL36B mRNA ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL36B mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr 3:7,024,881...7,030,388
Ensembl chr 3:7,021,973...7,031,619
|
|
G |
Il36g |
interleukin 36, gamma |
multiple interactions increases expression |
ISO |
ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL36G mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr 3:6,948,323...6,954,485
Ensembl chr 3:6,948,297...6,954,480
|
|
G |
Il36rn |
interleukin 36 receptor antagonist |
multiple interactions increases expression |
ISO |
ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL36RN mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr 3:7,044,419...7,051,016
Ensembl chr 3:7,044,406...7,051,016
|
|
G |
Il4 |
interleukin 4 |
increases secretion |
ISO |
Imiquimod results in increased secretion of IL4 protein |
CTD |
PMID:34740670 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression increases secretion |
ISO |
[Imiquimod binds to and results in increased activity of TLR7 protein] which results in increased secretion of IL6 protein; concanamycin B inhibits the reaction [Imiquimod results in increased secretion of IL6 protein]; hispidulin inhibits the reaction [Imiquimod results in increased expression of IL6 mRNA]; LGMN gene mutant form inhibits the reaction [Imiquimod results in increased secretion of IL6 protein]; MV026630 inhibits the reaction [Imiquimod results in increased secretion of IL6 protein] [Hydroxychloroquine co-treated with Imiquimod] results in increased secretion of IL6 protein; Cannabidiol promotes the reaction [Imiquimod results in increased secretion of IL6 protein] |
CTD |
PMID:21097750 PMID:22916010 PMID:31082466 PMID:31093508 PMID:31383729 PMID:32679548 PMID:34740670 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il7 |
interleukin 7 |
increases expression multiple interactions |
ISO |
Imiquimod results in increased expression of IL7 mRNA ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL7 mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr 2:94,235,219...94,280,075
Ensembl chr 2:94,234,766...94,280,075
|
|
G |
Il7r |
interleukin 7 receptor |
multiple interactions increases expression |
ISO |
ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL7R mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757
|
|
G |
Il9r |
interleukin 9 receptor |
decreases expression multiple interactions |
ISO |
Imiquimod results in decreased expression of IL9R mRNA ferulic acid inhibits the reaction [Imiquimod results in decreased expression of IL9R mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr10:15,431,706...15,444,144
Ensembl chr10:15,431,706...15,441,990
|
|
G |
Irak2 |
interleukin-1 receptor-associated kinase 2 |
multiple interactions increases expression |
ISO |
ferulic acid inhibits the reaction [Imiquimod results in increased expression of IRAK2 mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr 4:146,786,004...146,842,615
Ensembl chr 4:146,786,100...146,842,602
|
|
G |
Irak3 |
interleukin-1 receptor-associated kinase 3 |
increases expression multiple interactions |
ISO |
Imiquimod results in increased expression of IRAK3 mRNA ferulic acid inhibits the reaction [Imiquimod results in increased expression of IRAK3 mRNA] |
CTD |
PMID:31054998 |
|
NCBI chr 7:55,653,949...55,714,371
Ensembl chr 7:55,653,962...55,713,121
|
|
G |
Itgax |
integrin subunit alpha X |
multiple interactions |
ISO |
[imiquimod binds to and results in increased activity of TLR7 protein] which results in increased expression of ITGAX protein; Tetrachlorodibenzodioxin inhibits the reaction [[imiquimod binds to and results in increased activity of TLR7 protein] which results in increased expression of ITGAX protein] |
CTD |
PMID:21097750 |
|
NCBI chr 1:182,709,653...182,740,709
Ensembl chr 1:182,719,609...182,740,698
|
|
G |
Kif22 |
kinesin family member 22 |
decreases expression |
ISO |
imiquimod results in decreased expression of KIF22 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr 1:181,635,347...181,650,351
Ensembl chr 1:181,635,183...181,650,401
|
|
G |
Lgmn |
legumain |
increases activity multiple interactions |
ISO |
Imiquimod results in increased activity of LGMN protein LGMN gene mutant form inhibits the reaction [Imiquimod results in increased cleavage of TLR7 protein]; LGMN gene mutant form inhibits the reaction [Imiquimod results in increased expression of CD40 protein]; LGMN gene mutant form inhibits the reaction [Imiquimod results in increased expression of CD86 protein]; LGMN gene mutant form inhibits the reaction [Imiquimod results in increased secretion of IL12B protein]; LGMN gene mutant form inhibits the reaction [Imiquimod results in increased secretion of IL6 protein] |
CTD |
PMID:22916010 |
|
NCBI chr 6:121,544,048...121,582,495
Ensembl chr 6:121,544,053...121,582,480
|
|
G |
Lig1 |
DNA ligase 1 |
decreases expression |
ISO |
imiquimod results in decreased expression of LIG1 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr 1:74,165,688...74,204,400
Ensembl chr 1:74,165,842...74,204,413
|
|
G |
Lrch4 |
leucine rich repeats and calponin homology domain containing 4 |
multiple interactions |
ISO |
LRCH4 protein promotes the reaction [Imiquimod results in increased expression of TNF protein] |
CTD |
PMID:30523158 |
|
NCBI chr12:19,057,582...19,072,573
Ensembl chr12:19,057,587...19,068,577
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
ISO |
imiquimod results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:20033192 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation |
ISO |
imiquimod results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:20033192 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mlh1 |
mutL homolog 1 |
decreases expression |
ISO |
imiquimod results in decreased expression of MLH1 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity |
ISO |
imiquimod results in decreased activity of MMP9 protein |
CTD |
PMID:14708627 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpg |
N-methylpurine-DNA glycosylase |
decreases expression |
ISO |
imiquimod results in decreased expression of MPG mRNA |
CTD |
PMID:21878529 |
|
NCBI chr10:15,396,246...15,402,528
Ensembl chr10:15,395,782...15,402,520
|
|
G |
Mpo |
myeloperoxidase |
increases activity increases expression multiple interactions |
ISO |
imiquimod results in increased activity of MPO protein Imiquimod results in increased expression of MPO protein (+)-JQ1 compound inhibits the reaction [Imiquimod results in increased activity of MPO protein]; hispidulin inhibits the reaction [Imiquimod results in increased expression of MPO protein]; SR 1078 inhibits the reaction [(+)-JQ1 compound inhibits the reaction [Imiquimod results in increased activity of MPO protein]] |
CTD |
PMID:26149470 PMID:32679548 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
decreases expression |
ISO |
imiquimod results in decreased expression of MRE11A mRNA |
CTD |
PMID:21878529 |
|
NCBI chr 8:11,618,876...11,680,451
Ensembl chr 8:11,632,354...11,678,279
|
|
G |
Msh2 |
mutS homolog 2 |
decreases expression |
ISO |
imiquimod results in decreased expression of MSH2 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938
|
|
G |
Nudt1 |
nudix hydrolase 1 |
decreases expression |
ISO |
imiquimod results in decreased expression of NUDT1 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr12:14,302,514...14,309,559
Ensembl chr12:14,302,694...14,305,826
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
[resveratrol co-treated with imiquimod] results in increased expression of PCK1 mRNA |
CTD |
PMID:25965695 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pcna |
proliferating cell nuclear antigen |
increases expression multiple interactions |
ISO |
Imiquimod results in increased expression of PCNA protein Chloroquine inhibits the reaction [Imiquimod results in increased expression of PCNA protein] |
CTD |
PMID:36002070 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pms2 |
PMS1 homolog 2, mismatch repair system component |
decreases expression |
ISO |
imiquimod results in decreased expression of PMS2 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr12:10,676,818...10,701,161
Ensembl chr12:10,676,764...10,701,066
|
|
G |
Pole |
DNA polymerase epsilon, catalytic subunit |
decreases expression |
ISO |
imiquimod results in decreased expression of POLE mRNA |
CTD |
PMID:21878529 |
|
NCBI chr12:46,345,420...46,393,984
Ensembl chr12:46,345,420...46,393,939
|
|
G |
Poll |
DNA polymerase lambda |
decreases expression |
ISO |
imiquimod results in decreased expression of POLL mRNA |
CTD |
PMID:21878529 |
|
NCBI chr 1:244,400,202...244,408,762
Ensembl chr 1:244,400,204...244,408,662
|
|
G |
Ppp1r3c |
protein phosphatase 1, regulatory subunit 3C |
multiple interactions |
ISO |
[resveratrol co-treated with imiquimod] results in decreased expression of PPP1R3C mRNA |
CTD |
PMID:25965695 |
|
NCBI chr 1:234,460,958...234,465,961
Ensembl chr 1:234,460,652...234,465,961
|
|
G |
Rad51ap1 |
RAD51 associated protein 1 |
decreases expression |
ISO |
imiquimod results in decreased expression of RAD51AP1 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr 4:159,759,454...159,772,473
Ensembl chr 4:159,759,459...159,772,524
|
|
G |
Rad51d |
RAD51 paralog D |
decreases expression |
ISO |
imiquimod results in decreased expression of RAD51D mRNA |
CTD |
PMID:21878529 |
|
NCBI chr10:67,805,720...67,824,452
Ensembl chr10:67,740,712...67,824,434
|
|
G |
Rad54l |
RAD54 like |
decreases expression |
ISO |
imiquimod results in decreased expression of RAD54L mRNA |
CTD |
PMID:21878529 |
|
NCBI chr 5:129,575,431...129,605,100
Ensembl chr 5:129,575,378...129,605,070
|
|
G |
Rorc |
RAR-related orphan receptor C |
increases expression multiple interactions |
ISO |
imiquimod results in increased expression of RORC mRNA; imiquimod results in increased expression of RORC protein (+)-JQ1 compound inhibits the reaction [imiquimod results in increased expression of RORC mRNA]; (+)-JQ1 compound inhibits the reaction [imiquimod results in increased expression of RORC protein] |
CTD |
PMID:26149470 |
|
NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907
|
|
G |
Ruvbl2 |
RuvB-like AAA ATPase 2 |
decreases expression |
ISO |
imiquimod results in decreased expression of RUVBL2 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr 1:95,902,014...95,915,247
Ensembl chr 1:95,901,701...95,915,342
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
multiple interactions |
ISO |
imiquimod inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
imiquimod inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904
|
|
G |
Ssrp1 |
structure specific recognition protein 1 |
decreases expression |
ISO |
imiquimod results in decreased expression of SSRP1 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr 3:70,124,371...70,134,481
Ensembl chr 3:70,118,655...70,134,482
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases expression |
ISO |
imiquimod results in increased expression of STAT3 mRNA |
CTD |
PMID:26149470 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases secretion |
ISO |
Imiquimod results in increased secretion of TGFB1 protein |
CTD |
PMID:34740670 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
imiquimod results in increased expression of TIMP1 protein |
CTD |
PMID:14708627 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tlr7 |
toll-like receptor 7 |
multiple interactions increases cleavage affects binding |
ISO |
[Imiquimod binds to and results in increased activity of TLR7 protein] results in increased secretion of [IL12A protein binds to IL12B protein]; [Imiquimod binds to and results in increased activity of TLR7 protein] which results in increased expression of CD86 protein; [Imiquimod binds to and results in increased activity of TLR7 protein] which results in increased expression of ICAM1 protein; [Imiquimod binds to and results in increased activity of TLR7 protein] which results in increased expression of ITGAX protein; [Imiquimod binds to and results in increased activity of TLR7 protein] which results in increased secretion of IL6 protein; LGMN gene mutant form inhibits the reaction [Imiquimod results in increased cleavage of TLR7 protein]; Tetrachlorodibenzodioxin inhibits the reaction [[Imiquimod binds to and results in increased activity of TLR7 protein] results in increased secretion of [IL12A protein binds to IL12B protein]]; Tetrachlorodibenzodioxin inhibits the reaction [[Imiquimod binds to and results in increased activity of TLR7 protein] which results in increased expression of ITGAX protein]; Tetrachlorodibenzodioxin promotes the reaction [[Imiquimod binds to and results in increased activity of TLR7 protein] which results in increased expression of CD86 protein]; Tetrachlorodibenzodioxin promotes the reaction [[Imiquimod binds to and results in increased activity of TLR7 protein] which results in increased expression of ICAM1 protein] Imiquimod binds to TLR7 protein |
CTD |
PMID:21097750 PMID:22916010 PMID:31093508 |
|
NCBI chr X:27,027,380...27,054,309
Ensembl chr X:27,027,425...27,054,754
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion increases expression |
ISO |
CGP 57380 inhibits the reaction [Imiquimod results in increased expression of TNF protein]; hispidulin inhibits the reaction [Imiquimod results in increased expression of TNF protein]; LRCH4 protein promotes the reaction [Imiquimod results in increased expression of TNF protein] Cannabidiol promotes the reaction [Imiquimod results in increased secretion of TNF protein] Imiquimod results in increased expression of TNF mRNA; Imiquimod results in increased expression of TNF protein |
CTD |
PMID:18032482 PMID:25965695 PMID:26149470 PMID:30523158 PMID:31093508 PMID:32679548 PMID:34740670 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trex1 |
three prime repair exonuclease 1 |
increases expression |
ISO |
imiquimod results in increased expression of TREX1 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr 8:109,706,613...109,707,913
Ensembl chr 8:109,706,613...109,708,796
|
|
G |
Trim63 |
tripartite motif containing 63 |
multiple interactions |
ISO |
[resveratrol co-treated with imiquimod] results in increased expression of TRIM63 mRNA |
CTD |
PMID:25965695 |
|
NCBI chr 5:146,533,492...146,547,332
Ensembl chr 5:146,533,507...146,547,322
|
|
G |
Uhrf1 |
ubiquitin-like with PHD and ring finger domains 1 |
decreases expression |
ISO |
imiquimod results in decreased expression of UHRF1 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr 9:1,133,117...1,154,639
Ensembl chr 9:1,134,909...1,154,631
|
|
G |
Wrnip1 |
WRN helicase interacting protein 1 |
decreases expression |
ISO |
imiquimod results in decreased expression of WRNIP1 mRNA |
CTD |
PMID:21878529 |
|
NCBI chr17:31,621,410...31,641,659
Ensembl chr17:31,621,411...31,641,659
|
|
G |
Xpc |
XPC complex subunit, DNA damage recognition and repair factor |
increases expression |
ISO |
imiquimod results in increased expression of XPC mRNA |
CTD |
PMID:21878529 |
|
NCBI chr 4:123,993,670...124,020,922
Ensembl chr 4:123,993,666...124,021,010
|
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
multiple interactions increases degradation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [resiquimod results in increased degradation of APPL1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr16:2,118,503...2,166,741
Ensembl chr16:2,121,255...2,166,692
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
resiquimod results in increased phosphorylation of and results in increased degradation of CHUK protein 2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide inhibits the reaction [resiquimod results in increased phosphorylation of and results in increased degradation of CHUK protein]; 7-oxozeanol inhibits the reaction [resiquimod results in increased phosphorylation of and results in increased degradation of CHUK protein] |
CTD |
PMID:28924041 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
[Protein Kinase Inhibitors results in decreased activity of IRAK4 protein] inhibits the reaction [resiquimod promotes the reaction [IRF5 protein binds to CXCL10 promoter]]; resiquimod promotes the reaction [IRF5 protein binds to CXCL10 promoter]; resiquimod promotes the reaction [RELA protein binds to CXCL10 promoter] |
CTD |
PMID:28924041 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions increases secretion increases expression |
ISO |
[resiquimod co-treated with Lipopolysaccharides] results in increased expression of IFNB1 mRNA; apilimod inhibits the reaction [resiquimod results in increased expression of IFNB1 mRNA]; apilimod inhibits the reaction [resiquimod results in increased secretion of IFNB1 protein] |
CTD |
PMID:15851485 PMID:24600036 |
|
NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Acetylmuramyl-Alanyl-Isoglutamine co-treated with resiquimod co-treated with IFNG protein] results in increased expression of [IL12A protein binds to IL12B protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with resiquimod co-treated with IFNG protein] results in increased expression of IL12A mRNA; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with resiquimod co-treated with IFNG protein] results in increased expression of IL12B mRNA; [beta-Glucans co-treated with resiquimod co-treated with IFNG protein] results in increased expression of IL12A mRNA; IFNG protein affects the reaction [[Zymosan co-treated with resiquimod] results in increased expression of IL10 protein]; IFNG protein promotes the reaction [[Zymosan co-treated with resiquimod] results in increased expression of [IL12A protein binds to IL12B protein]]; IFNG protein promotes the reaction [[Zymosan co-treated with resiquimod] results in increased expression of [IL12B protein binds to IL23A protein]]; IFNG protein promotes the reaction [[Zymosan co-treated with resiquimod] results in increased expression of IL12B protein]; resiquimod promotes the reaction [[Acetylmuramyl-Alanyl-Isoglutamine co-treated with Pam(3)CSK(4) peptide co-treated with IFNG protein] results in increased expression of [IL12A protein binds to IL12B protein]]; resiquimod promotes the reaction [[Acetylmuramyl-Alanyl-Isoglutamine co-treated with Pam(3)CSK(4) peptide co-treated with IFNG protein] results in increased expression of IL12B protein] resiquimod inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased secretion of IL12B protein] |
CTD |
PMID:18490488 PMID:23890009 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
increases phosphorylation multiple interactions |
ISO |
resiquimod results in increased phosphorylation of IKBKB protein 2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide promotes the reaction [resiquimod results in increased phosphorylation of IKBKB protein]; [Protein Kinase Inhibitors results in decreased activity of IRAK4 protein] inhibits the reaction [resiquimod results in increased phosphorylation of IKBKB protein] |
CTD |
PMID:28924041 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression increases secretion |
ISO |
[Zymosan co-treated with resiquimod] results in increased expression of IL10 protein; IFNG protein affects the reaction [[Zymosan co-treated with resiquimod] results in increased expression of IL10 protein]; resiquimod promotes the reaction [beta-Glucans results in increased expression of IL10 mRNA]; resiquimod promotes the reaction [beta-Glucans results in increased expression of IL10 protein] resiquimod results in increased expression of IL10 mRNA MYD88 gene mutant form inhibits the reaction [resiquimod results in increased expression of IL10 protein]; resiquimod results in increased expression of and results in increased secretion of IL10 protein resiquimod results in increased secretion of IL10 protein |
CTD |
PMID:16224278 PMID:17238832 PMID:18490488 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
[Acetylmuramyl-Alanyl-Isoglutamine co-treated with resiquimod co-treated with IFNG protein] results in increased expression of [IL12A protein binds to IL12B protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with resiquimod co-treated with IFNG protein] results in increased expression of IL12A mRNA; [beta-Glucans co-treated with resiquimod co-treated with IFNG protein] results in increased expression of IL12A mRNA; [beta-Glucans co-treated with resiquimod] results in increased expression of [IL12A protein binds to IL12B protein]; [resiquimod co-treated with Poly I-C] results in increased secretion of [IL12A protein binds to IL12B protein]; [Zymosan co-treated with resiquimod] results in increased expression of [IL12A protein binds to IL12B protein]; IFNG protein promotes the reaction [[Zymosan co-treated with resiquimod] results in increased expression of [IL12A protein binds to IL12B protein]]; resiquimod promotes the reaction [[Acetylmuramyl-Alanyl-Isoglutamine co-treated with Pam(3)CSK(4) peptide co-treated with IFNG protein] results in increased expression of [IL12A protein binds to IL12B protein]] [resiquimod co-treated with Lipopolysaccharides] results in increased secretion of [IL12A protein binds to IL12B protein] |
CTD |
PMID:15851485 PMID:18490488 PMID:35688559 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions increases expression |
ISO |
[Acetylmuramyl-Alanyl-Isoglutamine co-treated with resiquimod co-treated with IFNG protein] results in increased expression of [IL12A protein binds to IL12B protein]; [Acetylmuramyl-Alanyl-Isoglutamine co-treated with resiquimod co-treated with IFNG protein] results in increased expression of IL12B mRNA; [beta-Glucans co-treated with resiquimod] results in increased expression of [IL12A protein binds to IL12B protein]; [Lipopolysaccharides co-treated with resiquimod] results in increased expression of [IL12B protein binds to IL12B protein]; [Lipopolysaccharides co-treated with resiquimod] results in increased expression of [IL12B protein binds to IL23A protein]; [resiquimod co-treated with Poly I-C] results in increased secretion of [IL12A protein binds to IL12B protein]; [Zymosan co-treated with resiquimod] results in increased expression of [IL12A protein binds to IL12B protein]; [Zymosan co-treated with resiquimod] results in increased expression of [IL12B protein binds to IL23A protein]; [Zymosan co-treated with resiquimod] results in increased expression of IL12B protein; IFNG protein promotes the reaction [[Zymosan co-treated with resiquimod] results in increased expression of [IL12A protein binds to IL12B protein]]; IFNG protein promotes the reaction [[Zymosan co-treated with resiquimod] results in increased expression of [IL12B protein binds to IL23A protein]]; IFNG protein promotes the reaction [[Zymosan co-treated with resiquimod] results in increased expression of IL12B protein]; resiquimod promotes the reaction [[Acetylmuramyl-Alanyl-Isoglutamine co-treated with Pam(3)CSK(4) peptide co-treated with IFNG protein] results in increased expression of [IL12A protein binds to IL12B protein]]; resiquimod promotes the reaction [[Acetylmuramyl-Alanyl-Isoglutamine co-treated with Pam(3)CSK(4) peptide co-treated with IFNG protein] results in increased expression of IL12B protein]; resiquimod promotes the reaction [beta-Glucans results in increased expression of [IL12B protein binds to IL23A protein]]; resiquimod promotes the reaction [beta-Glucans results in increased expression of IL12B protein] resiquimod results in increased expression of IL12B protein [resiquimod co-treated with Lipopolysaccharides] results in increased secretion of [IL12A protein binds to IL12B protein]; resiquimod inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased secretion of IL12B protein]; Simvastatin promotes the reaction [resiquimod results in increased expression of IL12B protein] |
CTD |
PMID:15187114 PMID:15851485 PMID:18490488 PMID:23890009 PMID:35688559 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
PML protein promotes the reaction [[resiquimod co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; resiquimod promotes the reaction [deoxynivalenol results in increased expression of IL1B mRNA] |
CTD |
PMID:16687389 PMID:23430110 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il21 |
interleukin 21 |
increases expression multiple interactions |
ISO |
resiquimod results in increased expression of IL21 protein Niclosamide inhibits the reaction [resiquimod results in increased expression of IL21 protein] |
CTD |
PMID:33632240 |
|
NCBI chr 2:120,117,105...120,127,012
Ensembl chr 2:120,119,444...120,126,996
|
|
G |
Il23a |
interleukin 23 subunit alpha |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with resiquimod] results in increased expression of [IL12B protein binds to IL23A protein]; [Zymosan co-treated with resiquimod] results in increased expression of [IL12B protein binds to IL23A protein]; IFNG protein promotes the reaction [[Zymosan co-treated with resiquimod] results in increased expression of [IL12B protein binds to IL23A protein]]; resiquimod promotes the reaction [beta-Glucans results in increased expression of [IL12B protein binds to IL23A protein]]; resiquimod promotes the reaction [beta-Glucans results in increased expression of IL23A mRNA] |
CTD |
PMID:18490488 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression increases secretion |
ISO |
LGMN gene mutant form inhibits the reaction [resiquimod results in increased secretion of IL6 protein]; Niclosamide inhibits the reaction [resiquimod results in increased expression of IL6 protein]; resiquimod promotes the reaction [deoxynivalenol results in increased expression of IL6 mRNA] 2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide inhibits the reaction [resiquimod results in increased expression of IL6 protein]; 7-oxozeanol inhibits the reaction [resiquimod results in increased expression of IL6 protein]; [Protein Kinase Inhibitors results in decreased activity of IRAK4 protein] inhibits the reaction [resiquimod results in increased expression of IL6 protein] resiquimod results in increased expression of IL6 mRNA; resiquimod results in increased expression of IL6 protein |
CTD |
PMID:16687389 PMID:22916010 PMID:28924041 PMID:33632240 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irak4 |
interleukin-1 receptor-associated kinase 4 |
increases phosphorylation multiple interactions |
ISO |
resiquimod results in increased phosphorylation of IRAK4 protein [Protein Kinase Inhibitors results in decreased activity of IRAK4 protein] inhibits the reaction [resiquimod promotes the reaction [IRF5 protein binds to CXCL10 promoter]]; [Protein Kinase Inhibitors results in decreased activity of IRAK4 protein] inhibits the reaction [resiquimod promotes the reaction [IRF5 protein binds to TNF promoter]]; [Protein Kinase Inhibitors results in decreased activity of IRAK4 protein] inhibits the reaction [resiquimod results in increased expression of IL6 protein]; [Protein Kinase Inhibitors results in decreased activity of IRAK4 protein] inhibits the reaction [resiquimod results in increased expression of TNF protein]; [Protein Kinase Inhibitors results in decreased activity of IRAK4 protein] inhibits the reaction [resiquimod results in increased phosphorylation of IKBKB protein] |
CTD |
PMID:28924041 |
|
NCBI chr 7:125,682,502...125,708,294
Ensembl chr 7:125,682,488...125,717,837
|
|
G |
Irf5 |
interferon regulatory factor 5 |
multiple interactions |
ISO |
[Protein Kinase Inhibitors results in decreased activity of IRAK4 protein] inhibits the reaction [resiquimod promotes the reaction [IRF5 protein binds to CXCL10 promoter]]; [Protein Kinase Inhibitors results in decreased activity of IRAK4 protein] inhibits the reaction [resiquimod promotes the reaction [IRF5 protein binds to TNF promoter]]; resiquimod promotes the reaction [IRF5 protein binds to CXCL10 promoter]; resiquimod promotes the reaction [IRF5 protein binds to TNF promoter] |
CTD |
PMID:28924041 |
|
NCBI chr 4:58,127,577...58,140,665
Ensembl chr 4:58,127,640...58,139,267
|
|
G |
Lgmn |
legumain |
multiple interactions |
ISO |
LGMN gene mutant form inhibits the reaction [resiquimod results in increased secretion of IL6 protein]; LGMN gene mutant form inhibits the reaction [resiquimod results in increased secretion of TNF protein] |
CTD |
PMID:22916010 |
|
NCBI chr 6:121,544,048...121,582,495
Ensembl chr 6:121,544,053...121,582,480
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
MYD88 gene mutant form inhibits the reaction [resiquimod results in increased expression of IL10 protein] |
CTD |
PMID:17238832 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Pml |
PML nuclear body scaffold |
multiple interactions |
ISO |
PML protein promotes the reaction [[resiquimod co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein] |
CTD |
PMID:23430110 |
|
NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
resiquimod promotes the reaction [RELA protein binds to CXCL10 promoter]; resiquimod promotes the reaction [RELA protein binds to TNF promoter] |
CTD |
PMID:28924041 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sdc1 |
syndecan 1 |
increases expression multiple interactions |
ISO |
resiquimod results in increased expression of SDC1 protein Tetrachlorodibenzodioxin inhibits the reaction [resiquimod results in increased expression of SDC1 protein] |
CTD |
PMID:20348231 |
|
NCBI chr 6:31,562,799...31,585,267
Ensembl chr 6:31,562,739...31,585,264
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases expression |
ISO |
resiquimod results in increased expression of STAT3 mRNA |
CTD |
PMID:17238832 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tlr7 |
toll-like receptor 7 |
affects binding increases activity |
ISO |
resiquimod binds to TLR7 protein resiquimod results in increased activity of TLR7 protein |
CTD |
PMID:15851485 PMID:25780039 PMID:29122671 |
|
NCBI chr X:27,027,380...27,054,309
Ensembl chr X:27,027,425...27,054,754
|
|
G |
Tlr8 |
toll-like receptor 8 |
affects binding increases activity multiple interactions |
ISO |
resiquimod binds to TLR8 protein resiquimod results in increased activity of TLR8 protein bafilomycin A1 inhibits the reaction [resiquimod results in increased activity of TLR8 protein] |
CTD |
PMID:15851485 PMID:21398612 PMID:25780039 |
|
NCBI chr X:27,091,780...27,116,092
Ensembl chr X:27,091,778...27,116,549
|
|
G |
Tnf |
tumor necrosis factor |
increases expression increases secretion multiple interactions |
ISO |
resiquimod results in increased expression of TNF mRNA resiquimod results in increased secretion of TNF protein resiquimod results in increased expression of TNF mRNA; resiquimod results in increased expression of TNF protein 2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide inhibits the reaction [resiquimod results in increased expression of TNF protein]; 7-oxozeanol inhibits the reaction [resiquimod results in increased expression of TNF protein]; [Protein Kinase Inhibitors results in decreased activity of IRAK4 protein] inhibits the reaction [resiquimod promotes the reaction [IRF5 protein binds to TNF promoter]]; [Protein Kinase Inhibitors results in decreased activity of IRAK4 protein] inhibits the reaction [resiquimod results in increased expression of TNF protein]; resiquimod promotes the reaction [IRF5 protein binds to TNF promoter]; resiquimod promotes the reaction [RELA protein binds to TNF promoter] LGMN gene mutant form inhibits the reaction [resiquimod results in increased secretion of TNF protein]; resiquimod promotes the reaction [deoxynivalenol results in increased expression of TNF mRNA] |
CTD |
PMID:16687389 PMID:17238832 PMID:22916010 PMID:28924041 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|